Rising solutions for secondary treatment failure in patients on chronic botulinum neurotoxin therapy

Affiliations

¹ IRCCS Neuromed Institute, Pozzilli IS, Italy.
² IRCCS Neuromed Institute, Pozzilli IS, Italy; Department of Human Neurosciences, Sapienza University of Rome, Italy. Electronic address: antonio.suppa@uniroma1.it.

Editorial

G Leodori et al. Clin Neurophysiol. 2019 Jun.

. 2019 Jun;130(6):1031-1032.

doi: 10.1016/j.clinph.2019.03.002. Epub 2019 Mar 22.

¹ IRCCS Neuromed Institute, Pozzilli IS, Italy.
² IRCCS Neuromed Institute, Pozzilli IS, Italy; Department of Human Neurosciences, Sapienza University of Rome, Italy. Electronic address: antonio.suppa@uniroma1.it.

No abstract available

Comment on

Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
Kutschenko A, Weisemann J, Kollewe K, Fiedler T, Alvermann S, Böselt S, Escher C, Garde N, Gingele S, Kaehler SB, Karatschai R, Krüger THC, Sikorra S, Tacik P, Wegner F, Wollmann J, Bigalke H, Wohlfarth K, Rummel A. Kutschenko A, et al. Clin Neurophysiol. 2019 Jun;130(6):1066-1073. doi: 10.1016/j.clinph.2019.02.007. Epub 2019 Feb 28. Clin Neurophysiol. 2019. PMID: 30871800